Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionEx vivo expanded autologous human corneal epithelial cells containing stem cells
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentApproved
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat severe limbal stem cell deficiency (LSCD)
Regulatory Designation EU - Conditional Approval (Treat severe limbal stem cell deficiency (LSCD));
EU - Orphan Drug (Treat severe limbal stem cell deficiency (LSCD))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today